1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Exelixis’s Cabometyx Two-For-Two In A Week As Neuroendocrine Tumor Study Hits Endpoint

 
• By Alaric DeArment

The announcement of the CABINET study’s success follows by days positive results for CONTACT-02 in prostate cancer, though NETs represent a smaller commercial opportunity.

Exelixis said the Phase III CABINET trial in neuroendocrine tumors met its primary endpoint • Source: Shutterstock

Exelixis, Inc. got its second bit of good news in the space of a week with positive results from a pivotal trial of Cabometyx (cabozantinib) in pancreatic and extra-pancreatic neuroendocrine tumors (NETs), following closely the announcement of success in a study of the same drug in prostate cancer. On the other hand, while the NETs indication is one of significant unmet need, it may be relatively small in terms of revenue potential.

The company announced 24 August that the data and safety monitoring board (DSMB) of the National Cancer Institute-sponsored and Alliance for Clinical Trials in Oncology-led Phase III CABINET trial unanimously...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.